BMEA

Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.

Wall Street analysts forecast BMEA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMEA is 7.60 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Biomea Fusion Inc revenue for the last quarter amounts to -18.60M USD, decreased -45.36 % YoY.

Biomea Fusion Inc. EPS for the last quarter amounts to -11550000.00 USD, decreased -54.53 % YoY.

Biomea Fusion Inc (BMEA) has 106 emplpoyees as of January 10 2026.

Today BMEA has the market capitalization of 100.40M USD.